Table 2.
Key healthcare resources
| Parameters | Value | Source |
|---|---|---|
| Average days of treatment | [18, 40], expert opinion | |
| Oritavancin (IV) | 1 | |
| Vancomycin (IV) | 10.2 | |
| Linezolid (IV) | 13.7 | |
| Daptomycin (IV) | 11.1 | |
| Laboratory tests (per week) | [17, 40], expert opinion | |
| Chem7 | 1 × vancomycin; 1 × daptomycin; 1 × linezolid | |
| CBC levels | 1 × linezolid | |
| CPK levels | 1 × daptomycin | |
| Drug trough concentrations | 2 × vancomycin | |
| Hepatic panel | 1 × daptomycin | |
| Length of stay for hospitalized patients discharged to outpatient treatment (days) | ||
| Oritavancin (IV) | 2.5 | Assumption |
| Vancomycin (IV) | 4.1 | [18] |
| Linezolid (IV) | 4.42 | [18] |
| Daptomycin (IV) | 4.5 | [18] |
| Average time in observation (h) | 17.4 | [20, 21] |
CBC complete blood count, CPK creatine phosphokinase, IV intravenous